Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06212791
Other study ID # HM20027087
Secondary ID K23HL166956
Status Recruiting
Phase
First received
Last updated
Start date December 30, 2024
Est. completion date March 2028

Study information

Verified date January 2024
Source Virginia Commonwealth University
Contact Pamela Grizzard
Phone 804-628-6234
Email pamela.grizzard@vcuhealth.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Longitudinal, observational cohort study to evaluate changes in left atrial (LA) reservoir function during exercise and overall exertional capacity in patients following catheter ablation for paroxysmal atrial fibrillation (AF).


Description:

EXCLAMATORY is a longitudinal observational cohort clinical research study to evaluate the effects of catheter ablation for paroxysmal atrial fibrillation on left atrial and left ventricular performance during exercise, as well as effects on overall exercise capacity


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date March 2028
Est. primary completion date March 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Diagnosis of paroxysmal AF - Left ventricular ejection fraction =50% - Scheduled for catheter ablation - Able to speak, hear, and read English - Willing and able to provide informed consent Exclusion Criteria: - Persistent or permanent AF - Prior ablation (catheter based or surgical) for AF - Significant sinus node dysfunction - Implanted pacemaker or defibrillator - Contraindication to or inability to complete cardiovascular magnetic resonance study - Contraindication to or inability to complete exercise testing - Chronic kidney disease with estimated glomerular filtration rate <30 mL/min/1.73m2 - Severe left ventricular hypertrophy - Unrelated cardiomyopathy that is expected to limit exercise capacity, including but not limited to: - Hypertrophic cardiomyopathy - Cardiac amyloidosis - Constrictive pericarditis - Pulmonary arterial hypertension - Prior cardiac surgery - Active pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Self- Report Evaluation-Duke Activity Status Index
Complete the Self- Report Evaluation-Duke Activity Status Index
Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire
Complete the Self- Report Evaluation, Atrial Fibrillation Effect on Quality of Life Questionnaire
Diagnostic Test:
Cardiopulmonary exercise test (CPET)
Cardiopulmonary exercise test (CPET)
Transthoracic echocardiogram
Transthoracic echocardiogram at rest and immediately following peak exercise during CPET
Ambulatory cardiac rhythm assessment
Ambulatory cardiac rhythm assessment
Cardiovascular magnetic resonance (CMR)
Cardiovascular magnetic resonance (CMR) study at rest and during two stages of submaximal exercise (ExeCMR)

Locations

Country Name City State
United States Virginia Commonwealth University Richmond Virginia

Sponsors (2)

Lead Sponsor Collaborator
Virginia Commonwealth University National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in LA reservoir function reserve at submaximal exercise after catheter ablation in patients with paroxysmal AF. Change in LA reservoir volume reserve from baseline to follow up, change in left ventricular (LV) stroke volume reserve from baseline to follow up, correlation between changes in LA reservoir volume reserve and changes in LV stroke volume reserve. Therefore the follow up testing will be performed 5-6 months (to be more specific: 150-180 days) after catheter ablation. Baseline and the follow up testing will be performed 5-6 months (to be more specific: 150-180 days) after catheter ablation.
Secondary Change in LV stroke volume reserve at submaximal exercise after catheter ablation in patients with paroxysmal AF. Change in LA reservoir volume reserve from baseline to follow up, change in LV stroke volume reserve from baseline to follow up, correlation between changes in LA reservoir volume reserve and changes in LV stroke volume reserve. Baseline and the follow up testing will be performed 5-6 months (to be more specific: 150-180 days) after catheter ablation.
Secondary Correlation between changes in LA reservoir volume reserve and changes in LV stroke vol reserve after catheter ablation in patients with paroxysmal AF Correlation between changes in LA reservoir volume reserve and changes in LV stroke volume reserve after catheter ablation in patients with paroxysmal AF Baseline and the follow up testing will be performed 5-6 months (to be more specific: 150-180 days) after catheter ablation.
Secondary Correlation between changes in LA reservoir function reserve at submaximal exercise and changes in mixed venous oxygen tension (pVO2) . Correlation between changes in LA reservoir function reserve at submaximal exercise and changes in pVO2 after catheter ablation Baseline and the follow up testing will be performed 5-6 months (to be more specific: 150-180 days) after catheter ablation.
Secondary Correlation between changes in LV stroke volume reserve at submaximal exercise and changes in pVO2 Correlation between changes in LV stroke volume reserve at submaximal exercise and changes in pVO2 after catheter ablation. Baseline and the follow up testing will be performed 5-6 months (to be more specific: 150-180 days) after catheter ablation.
Secondary Correlation between baseline AF burden and LA function, LV Function and pVO2 Correlation between baseline AF burden and LA function (rest and exercise), LV function (rest and exercise), and pVO2 Baseline and the follow up testing will be performed 5-6 months (to be more specific: 150-180 days) after catheter ablation.
Secondary Correlation between the amount of AF burden reduction and the changes in LA function, LV function (rest and exercise), and pVO2. Correlation between the amount of AF burden reduction and the changes in LA function (rest and exercise), LV function (rest and exercise), and pVO2. Baseline and the follow up testing will be performed 5-6 months (to be more specific: 150-180 days) after catheter ablation.
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT06014996 - Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation. N/A
Completed NCT03624881 - Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU) Phase 4
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Recruiting NCT05905835 - Treatment of PAF With the Synaptic System N/A
Active, not recruiting NCT05618340 - PFA for Paroxysmal Atrial Fibrillation N/A
Active, not recruiting NCT05534581 - Comparison of Cryoballoon vs. Pulsed Field Ablation in Patients With Symptomatic Paroxysmal Atrial Fibrillation Phase 4
Not yet recruiting NCT05974098 - Quality of Life Influencing Factors
Not yet recruiting NCT05024630 - Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension N/A
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01913522 - Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration N/A
Withdrawn NCT01917981 - Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation Phase 3
Terminated NCT01925885 - Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF) N/A
Completed NCT01693107 - Atrial Fibrillation Force Contact Ablation Study
Completed NCT01842529 - Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery Phase 2
Completed NCT00971204 - Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation Phase 2
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Recruiting NCT05172765 - Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF) N/A
Recruiting NCT04529785 - Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific